

RESEARCH ARTICLE

The Parkinson's disease gene *PINK1* activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P₃

Rachel M. Furlong^{1,2,3}, Andrew Lindsay¹, Karen E. Anderson⁴, Phillip T. Hawkins⁴, Aideen M. Sullivan^{2,3,*} and Cora O'Neill^{1,3,*,†}

ABSTRACT

Akt signalling is central to cell survival, metabolism, protein and lipid homeostasis, and is impaired in Parkinson's disease (PD). Akt activation is reduced in the brain in PD, and by many PD-causing genes, including *PINK1*. This study investigated the mechanisms by which *PINK1* regulates Akt signalling. Our results reveal for the first time that *PINK1* constitutively activates Akt in a *PINK1*-kinase dependent manner in the absence of growth factors, and enhances Akt activation in normal growth medium. In *PINK1*-modified MEFs, agonist-induced Akt signalling failed in the absence of *PINK1*, due to *PINK1* kinase-dependent increases in PI(3,4,5)P₃ at both plasma membrane and Golgi being significantly impaired. In the absence of *PINK1*, PI(3,4,5)P₃ levels did not increase in the Golgi, and there was significant Golgi fragmentation, a recognised characteristic of PD neuropathology. *PINK1* kinase activity protected the Golgi from fragmentation in an Akt-dependent fashion. This study demonstrates a new role for *PINK1* as a primary upstream activator of Akt via *PINK1* kinase-dependent regulation of its primary activator PI(3,4,5)P₃, providing novel mechanistic information on how loss of *PINK1* impairs Akt signalling in PD.

This article has an associated First Person interview with the first author of the paper.

KEY WORDS: Akt, Parkinson's disease, *PINK1*, neurodegeneration, PIP₃

INTRODUCTION

PINK1 [phosphatase and tensin homologue (PTEN)-induced putative kinase 1] was identified as a gene upregulated by overexpression of the tumor suppressor PTEN, the major negative regulator of phosphoinositide-3-kinase (PI3-kinase)–Akt signalling (Unoki and Nakamura, 2001). Subsequently, loss-of-function mutations in *PINK1* were reported to cause autosomal recessive early onset Parkinson's disease (PD) (Valente et al., 2004), leading to a major research effort to understand *PINK1* function. *PINK1*, a ubiquitous serine-threonine kinase, has pro-survival, neuroprotective and anti-stress signalling functions (Arena et al., 2013; Haque et al., 2008; Li et al., 2017; MacKeigan et al., 2005; Wood-Kaczmar et al., 2008; Yang et al., 2018). Multiple studies, from our and other

labs, have shown that *PINK1* is a key regulator of mitochondrial health, including mitophagy, fission, fusion, bioenergetics and mitochondrial antigen presentation (Harper et al., 2018; Matheoud et al., 2016; O'Flanagan et al., 2015; Pilsl and Winklhofer, 2012; Youle and Narendra, 2011; Youle and van der Bliek, 2012). Although these are the most widely documented functions of *PINK1*, it also regulates several other non-mitochondrial systems central to survival, neuroprotection and stress resistance (Dagda et al., 2009, 2014; Dickey and Strack, 2011; Fedorowicz et al., 2014; Ries et al., 2006; Steer et al., 2015; Xiong et al., 2009; for review see Arena and Valente, 2017; O'Flanagan and O'Neill, 2014). These include PI3-kinase–Akt signalling (Akundi et al., 2012; Contreras-Zarate et al., 2015; Ellis et al., 2013; Maj et al., 2010; Sánchez-Mora et al., 2012), the cell cycle (O'Flanagan et al., 2015), protein kinase A (Dagda et al., 2014; Dickey and Strack, 2011), NF-κB (Lee and Chung, 2012; Lee et al., 2012; Sha et al., 2010), ubiquitination, proteasomal degradation (Xiong et al., 2009) and macroautophagy (Dagda et al., 2009; Fedorowicz et al., 2014).

Understanding the interactions between *PINK1* and the PI3-kinase–Akt pathway is of central importance for PD research, as this pathway is a master regulator of cell survival, metabolism and proteostasis, key systems that fail in PD (Manning and Toker, 2017). In concordance, in comparison with non-PD samples, Akt activation is impaired in postmortem tissue from the substantia nigra of PD patients (Malagelada et al., 2008; Timmons et al., 2009), and constitutive activation of Akt protects against dopaminergic neuron loss in a preclinical model of PD (Ries et al., 2006). Notably, several PD risk genes, including *PINK1*, converge to crosstalk with the PI3-kinase–Akt signalling system (Chuang et al., 2014; Fallon et al., 2006; Gupta et al., 2017; Jaramillo-Gómez et al., 2015; Kim et al., 2005; Ohta et al., 2011; Zhang et al., 2016). Akt activation by *PINK1* confers protection against several cell stressors including rotenone (Murata et al., 2011), calyculin A, FK506, staurosporine (Akundi et al., 2012) and ceramide (Contreras-Zarate et al., 2015; Sánchez-Mora et al., 2012). Akt-induced inhibition of FOXO3a can reduce *PINK1* mRNA levels (Mei et al., 2009), and Akt signalling regulates *PINK1*-dependent mitophagy (Deas et al., 2011; Hauser et al., 2017; Matsuda et al., 2010; McCoy et al., 2014; Soutar et al., 2018).

Akt activation mechanisms and Akt signalling are the subject of intensive investigation in cell biology in health and disease (for review see Manning and Toker, 2017). Accumulation of the membrane lipid phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P₃ or PIP₃], via agonist-induced phosphorylation of PI(4,5)P₂ by PI3-kinases, is an essential prerequisite for Akt activation. PIP₃ acts by recruiting inactive cytosolic Akt to membranes by interacting with its pleckstrin homology (PH) domain (Bellacosa et al., 1998). This interaction induces a conformational change in Akt, essential for Akt activation, allowing phosphorylation at two regulatory residues, Ser⁴⁷³ by mammalian target of rapamycin complex 2 (mTORC2) (Alessi et al.,

¹School of Biochemistry and Cell Biology, Biosciences Institute, University College Cork, Cork City T12 YT20, Ireland. ²Department of Anatomy and Neuroscience, Western Gateway Building, University College Cork, Cork City T12 XF62, Ireland.

³Cork Neuroscience Centre, University College Cork, Cork City T12 YT20, Ireland.

⁴Signalling Programme, Babraham Institute, Cambridge CB22 3AT, UK.

*These authors contributed equally to this work

†Author for correspondence (c.oneill@ucc.ie)

© C.O., 0000-0001-5386-7415

1996; Sarbassov et al., 2005; Stokoe et al., 1997), and Thr³⁰⁸, by phosphoinositide-dependent kinase 1 (PDK1, also known as PDKP1) (Calleja et al., 2007; Stokoe et al., 1997). Termination of PI3-kinase–PIP₃–Akt signalling is predominantly due to dephosphorylation of PIP₃ to PI(4,5)P₂ by the phosphatase PTEN (Maehama and Dixon, 1998; Stokoe et al., 1997). It is increasingly recognised that PIP₃ can equilibrate between endomembranes via membrane trafficking routes, and can also be generated within endomembranes *in situ* (Braccini et al., 2015; Ebner et al., 2017; Jethwa et al., 2015; Salamon and Backer, 2013; Sato et al., 2003). The observation that Akt localises to endomembranes, in addition to the plasma membrane, has led to the modification of Akt signalling models to incorporate compartment-specific patterns of activation (Ebner et al., 2017; Manning and Toker, 2017).

While it is clear that PINK1 can activate Akt (Akundi et al., 2012; Boonying et al., 2019; Contreras-Zárate et al., 2015; Ellis et al., 2013; Hauser et al., 2017; Maj et al., 2010; Mei et al., 2009; Murata et al., 2011; O’Flanagan and O’Neill, 2014; Sánchez-Mora et al., 2012; Soutar et al., 2018), and that PINK1 deletion reduces Akt activation, the mechanism by which this occurs and its dependence on PINK1 kinase activity remain unclear. Initial studies revealed that PINK1 markedly enhanced the phosphorylation of Akt at Ser⁴⁷³ but not Thr³⁰⁸, inducing Akt activation that was essential for protection from a variety of cytotoxic agents (Murata et al., 2011). PINK1-induced Akt activation was reported to occur independently of PI3-kinases, via PINK1-mediated activation of mTORC2 via Rictor (Murata et al., 2011). In contrast, subsequent studies revealed that mouse embryonic fibroblasts (MEFs) from PINK1^{-/-} mice had reduced IGF-1- and insulin-induced activation of Akt, with reduced phosphorylation at both Akt activation residues, Thr³⁰⁸ and Ser⁴⁷³, and protection from apoptosis and metabolic dysfunction (Akundi et al., 2012). Together, these studies show that PINK1 promotes Akt activation via a mechanism upstream of Akt phosphorylation (Akundi et al., 2012; Contreras-Zárate et al., 2015; Ellis et al., 2013; Maj et al., 2010; Manning and Toker, 2017; Mei et al., 2009; Murata et al., 2011; Sánchez-Mora et al., 2012). However, various mechanisms have been proposed and there is no clear information on whether Akt activation requires PINK1 kinase activity.

In this study, we employed PINK1-modified cell systems (Morais et al., 2009; O’Flanagan et al., 2015) to investigate the mechanism by which PINK1 activates Akt. We identify PINK1 as a major upstream activator of Akt, and provide a new mechanism involving PINK1 kinase-dependent regulation of the plasma membrane and endomembrane localisation of PIP₃, the essential lipid activator of Akt. This study significantly advances knowledge on the mechanisms by which loss of function of PINK1 impairs Akt activation in PD.

RESULTS

PINK1 activates Akt in a PINK1 kinase-dependent manner

Initial results show that terminally-differentiated mouse embryonic fibroblasts (MEFs) derived from PINK1^{-/-} mice (Morais et al., 2009; O’Flanagan et al., 2015) displayed significantly reduced Akt phosphorylation at both Ser⁴⁷³ and Thr³⁰⁸ activating residues when cultured in normal growth medium (Fig. 1A). Total Akt levels were equivalent in PINK1^{-/-} and PINK1^{+/+} cells, indicating that deletion of PINK1 significantly reduced activation of Akt (phospho-Akt/Akt ratio). These findings were confirmed in BE(2)-M17 neuroblastoma cells transduced with shRNA to PINK1 (Fig. 1B). Stable expression of human PINK1 (hPINK1_{res}) in PINK1^{-/-} MEFs fully restored phosphorylation at the Ser⁴⁷³ residue

($P < 0.05$), and partially restored phosphorylation at Thr³⁰⁸ ($P = 0.09$) (Fig. 1A). In contrast, a triple kinase-dead PINK1 mutant (hPINK1_{TKD}) did not restore phosphorylation at either residue (Fig. 1A). Deletion of PINK1 did not alter Akt1, Akt2 or Akt3 isoform levels; however expression of hPINK1_{TKD} resulted in a significant decrease in the level of Akt1, which indicates that PINK1 kinase activity can specifically regulate the levels of Akt1 (Fig. 1C). We further demonstrate that PINK1 overexpression in PINK1^{-/-} MEFs resulted in constitutive activation of Akt at both activating residues, in the absence of serum, whereas Akt activation was markedly impaired in wild type, PINK1^{-/-} and hPINK1_{TKD} mutants (Fig. 1D). Total Akt levels were similar in all cell lines (Fig. 1D). Together, these data show that PINK1 activates Akt by inducing phosphorylation at both the mTORC2-dependent Ser⁴⁷³ and PDK1-dependent Thr³⁰⁸ activation sites, without affecting Akt isoform levels. Additionally, these results indicate that PINK1 can constitutively activate Akt, even in the absence of serum, and that this requires PINK1 kinase activity.

Plasma membrane localisation of Akt is enhanced by PINK1 kinase activity

GFP–Akt–PH transfection allows visualisation of Akt plasma membrane localisation (Calleja et al., 2007; Ebner et al., 2017; Meyer et al., 2012), which is known to be critical for Akt activation (Bellacosa et al., 1998). We next examined whether increased Akt activation induced by PINK1 was mechanistically associated with increased recruitment of Akt to the plasma membrane. Our results show that, under normal growth conditions, GFP–Akt–PH was localised to the plasma membrane at a number of focal points, where clear areas with increased GFP–Akt–PH were evident in PINK1^{+/+} and hPINK1_{res} cells, but not in PINK1^{-/-} and hPINK1_{TKD} MEFs (Fig. 2A). This was visualised by analysis of the fluorescence intensity along a line that bisected the cell, with sharp peaks of fluorescence intensity observed where the line crosses the plasma membrane in PINK1^{+/+} and hPINK1_{res} cells but not in PINK1^{-/-} and hPINK1_{TKD} MEFs (Fig. S1A). The percentage of cells with GFP–Akt–PH at the plasma membrane was quantified, revealing a significant reduction in PINK1^{-/-} and hPINK1_{TKD} MEFs ($P < 0.0001$) in comparison to PINK1^{+/+} and hPINK1_{res} MEFs (Fig. 2B).

This impairment in GFP–Akt–PH localisation to the plasma membrane was also evident in PINK1^{-/-} and hPINK1_{TKD} cells in response to the agonist IGF-1, a major activator of Akt (Fig. 3). In unstimulated cells, GFP–Akt–PH was distributed diffusely throughout the cytoplasm in all four MEF cell lines (Fig. 3A). After 2-min stimulation with IGF-1, a rapid and significant increase in the percentage of cells with GFP–Akt–PH at the plasma membrane was evident in both PINK1^{+/+} and hPINK1_{res} MEFs. This was significantly lower ($P < 0.0001$), remaining at baseline levels, in both PINK1^{-/-} or hPINK1_{TKD} MEFs (Fig. 3A,B). The percentage of cells displaying plasma membrane localisation of GFP–Akt–PH in the PINK1^{-/-} and hPINK1_{TKD} cells increased following 10-min IGF-1 stimulation, but remained significantly lower than that observed in PINK1^{+/+} and hPINK1_{res} MEFs cell lines ($P = 0.0002$) (Fig. 3B). Plasma membrane localisation of full length GFP–Akt is also enhanced by PINK1 kinase activity in the same manner, verifying that this is not due to truncation of Akt (Fig. S2). Thus, it can be concluded that the localisation of Akt at the plasma membrane, which is known to be critical for Akt activation, is regulated by PINK1 kinase activity, both under normal growth conditions and in response to short-term stimulation with IGF-1.




Fig. 1. See next page for legend.

Fig. 1. PINK1 is a major regulator of Akt activation. (A) Representative immunoblot analysis showing phosphorylation of Akt at Ser⁴⁷³ and Thr³⁰⁸ in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, which were grown for 24 h in DMEM-Hi supplemented with 10% FBS. (B) Representative immunoblot analysis showing phosphorylation of Akt at Ser⁴⁷³ and Thr³⁰⁸ in BE(2)-M17 cells, which were grown for 24 h in DMEM-Hi supplemented with 10% FBS. (C) Representative immunoblot analysis showing levels of Akt1, Akt2 and Akt3 in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, which were grown for 24 h in DMEM-Hi supplemented with 10% FBS. (D) Representative immunoblot analysis showing phosphorylation of Akt at Ser⁴⁷³ and Thr³⁰⁸ in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, which were grown in the absence of serum. Data information: In A–C, data are presented in corresponding graphs as mean±s.e.m. (*n*=3 biological replicates for each). **P*<0.05, ***P*<0.01 and ****P*<0.0001 (one-way ANOVA) with respect to PINK1^{+/+} MEFs. #*P*<0.05 and ##*P*<0.01 with respect to hPINK1_{res} MEFs. In D, data are presented in corresponding graphs as mean±s.e.m. (*n*=3 biological replicates). ***P*<0.01 and ****P*<0.0001 (one-way ANOVA) with respect to PINK1^{+/+}, hPINK1_{res} and hPINK1_{TKD} MEFs.

PI3-kinase p85 α subunit phosphorylation is reduced in the absence of PINK1 kinase activity

Next, we sought to identify mechanisms by which PINK1 activates Akt. Firstly, we determined whether PINK1 regulated Akt activity by enhancing either PDK1- and/or mTORC2-induced phosphorylation of Akt^{Thr308} and Akt^{Ser473}, respectively. PDK1 activation was assessed indirectly by measuring PDK-1^{Ser241} phosphorylation (necessary for PDK-1 activation) (Casamayor et al., 1999; Komander et al., 2005; Wick et al., 2003), SGK-1 (a protein downstream of PDK-1 and regulated by its activation) (Castel et al., 2016; Hall et al., 2012)

and mTORC2 via Rictor levels (Sarbasov et al., 2004). Comparative western immunoblot analysis revealed that there was no significant alteration in PDK1^{Ser241}, SGK-1 or Rictor levels when comparing wild-type, PINK1^{-/-}, hPINK1_{res} or hPINK1_{TKD} cells (Fig. 4A).

Phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P₃ or PIP₃] accumulation in membranes is essential for the recruitment of Akt to membrane compartments for subsequent mTORC2- and PDK1-induced activation of Akt via phosphorylation of Akt at Ser⁴⁷³ and Thr³⁰⁸, respectively (Alessi et al., 1996; Manning and Toker, 2017). As PINK1 enhances Akt phosphorylation at both Ser⁴⁷³ and Thr³⁰⁸ sites, we hypothesised that PINK1 may regulate PI3-kinases and PTEN, the primary enzymes that control the synthesis and degradation of PIP₃, respectively (Hers et al., 2011). The levels of the PI3-kinase catalytic subunit p110 α (also known as PIK3CA) were not altered by PINK1 expression (Fig. 4B). However, activation of the regulatory subunit PI3-kinase p85 [composed of p85 α (PIK3R1) and p85 β (PIK3R2)], as measured by the phospho-p85 (pTyr458)/p85 α ratio (Aweida et al., 2018; Ibrahim et al., 2019; Pedrosa et al., 2019; Zheng et al., 2019), was significantly decreased by PINK1 deletion. This p85 activation was restored in hPINK1_{res}, but not in hPINK1_{TKD} (Fig. 4B). In contrast, neither total PTEN levels, nor its phosphorylation at Ser³⁸⁰ (inactivating residue), were significantly altered by PINK1 knockout or overexpression (Fig. 4C). Taken together, these data indicate that activation of Akt by PINK1 may be mechanistically linked to PI3-kinase phosphorylation, specifically the p85 regulatory subunit.




Fig. 2. PINK1 regulates the localisation of Akt to the plasma membrane. (A) Representative confocal images showing GFP–Akt–PH localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, which were grown in DMEM-Hi supplemented with 10% FBS, transfected with GFP–Akt–PH for 24 h and stained with DAPI (blue). White line shows path of fluorescence intensity analysis (see Fig. S1 for fluorescence intensity profiles). Scale bar: 10 μm. (B) Histogram depicting the percentage of transfected cells with Akt accumulations at the plasma membrane. Data are presented as mean±s.e.m. (*n*=3 biological replicates for each). ****P*<0.0001 with respect to PINK1^{+/+} MEFs. ###*P*<0.0001 with respect to PINK1^{-/-} MEFs and hPINK1_{TKD} MEFs (one-way ANOVA).





Fig. 3. PINK1 decreases the time taken for Akt to get to the plasma membrane in response to IGF-1 stimulation. (A) Representative confocal images showing GFP–Akt–PH localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, following transfection with GFP–Akt–PH for 24 h and stained with DAPI (blue). Serum-starved cells were stimulated with 10 ng/ml IGF-1 for the indicated times (*n*=3 biological replicates). White line shows path of fluorescence intensity analysis (see Fig. S1 for fluorescence intensity profiles). Scale bars: 10 μm. (B) Histograms depicting the percentage of transfected cells with Akt accumulations at the plasma membrane. Data are presented as mean±s.e.m. (*n*=3 biological replicates). ***P*<0.01 and ****P*<0.0001 with respect to PINK1^{+/+} MEFs. ##*P*<0.01 and ###*P*<0.0001 with respect to PINK1^{-/-} and hPINK1_{TKD} MEFs (one-way ANOVA).






Fig. 4. Phosphorylation and activation of PI3-kinases is PINK1 kinase-dependent. (A–C) Representative immunoblot analysis showing relative expression of proteins that regulate Akt activation through indicators of PDK-1 activation (A), PI3-kinase activity (B) or PTEN activity (C) in PINK1^{+/+}, PINK1^{-/-}, hPINK1^{res} and hPINK1^{TKD} MEFs, which were grown in DMEM-Hi supplemented with 10% FBS. Data are presented in corresponding graphs as mean±s.e.m. (*n*=3 biological replicates for each). **P*<0.05 and ***P*<0.01 with respect to PINK1^{+/+} MEFs and ##*P*<0.01 with respect to PINK1^{-/-} and hPINK1^{TKD} MEFs (one-way ANOVA).

PINK1 kinase activity regulates the dynamic subcellular localisation of PIP₃ at the plasma membrane and Golgi in response to IGF-1

Initial rapid plasma membrane and subsequent longer-term endomembrane localisation of PIP₃, particularly in the Golgi and ER, in response to agonists and/or growth factors are critical determinants of compartment-specific Akt activation (Ebner et al.,

2017; Jethwa et al., 2015; Manning and Toker, 2017; Sato et al., 2003). We employed a PIP₃-specific monoclonal antibody (Braccini et al., 2015; Moulton et al., 2010; Papakonstanti et al., 2007; Wang et al., 2010) to determine whether PINK1 modulated the subcellular localisation of PIP₃ under normal growth conditions and in response to short-term (2 min, 10 min) and longer-term (60 min) IGF-1 stimulation. Following 24 h serum deprivation, PIP₃ was diffusely

distributed throughout all cells (Fig. 5A). Non-uniform accumulations of PIP₃ at the plasma membrane in response to IGF-1 were evident in hPINK1_{res} after 2 min, but not in PINK1^{+/+}, PINK1^{-/-} or PINK1_{TKD} MEFs (Fig. 5A). After 10 min of IGF-1 stimulation, PIP₃ was observed at specific plasma membrane domains in all four cell lines (Fig. 5A). Importantly, PI3-kinase inhibition, by pretreatment with LY294002 (10 μM), prevented production of PIP₃ at the plasma membrane in PINK1^{+/+}, PINK1^{-/-} or PINK1_{TKD} MEFs. However, hPINK1_{res}-expressing cells had distinctly increased PIP₃ levels near the plasma membrane, in the presence of LY294002 10 μM (Fig. 5A) and also using increased concentrations of LY294002 50 μM (data not shown).

We observed that PIP₃ localises predominantly in the perinuclear region during normal growth conditions (Fig. 5B) compared to its localisation in distinctive loci at the plasma membrane following 10-min stimulation with IGF-1 (Fig. 5A). To determine the subcellular localisation of PIP₃ in this perinuclear region, we performed double immunofluorescence co-localisation analysis of PIP₃ with a number of selective endomembrane markers [Rab14, early endosomes; Rab11a, recycling endosomes; GRP-78 (also known as HSPA5 or BIP), endoplasmic reticulum; giantin (also known as GOLGB1), medial-Golgi; TGN46 (also known as TGOLN2), trans-Golgi; Lysotracker, lysosomes] (Fig. S3). We further sought to determine whether PINK1 deletion modified the localisation of PIP₃ within any specific endomembrane compartment. The results revealed a selective localisation of PIP₃ to the medial-Golgi, as the medial-Golgi protein, giantin, displayed the greatest colocalisation with PIP₃ (42.9% in PINK1^{+/+} and 48.3% hPINK1_{res} cells) (Fig. 5B). Notably, there was a significant reduction in the colocalisation of PIP₃ and giantin in PINK1^{-/-} and hPINK1_{TKD} MEFs (16.9% and 17.8%, respectively, *P*<0.0001) (Fig. 5B). Furthermore the colocalisation of PIP₃ within the medial-Golgi was selective, since PIP₃ colocalisation with the trans-Golgi marker, TGN46, and all other endomembrane markers was significantly lower than that measured for giantin (15–20%) and moreover was not altered by PINK1 deletion or PINK1 kinase activity (Fig. S3). The only exception to this was a significant reduction of PIP₃ colocalisation with Rab14 in PINK1^{-/-} cells (*P*<0.0005) compared to wild-type MEFs, although the colocalisation of PIP₃ was rather low in PINK1^{+/+} cells (27%). Moreover, the reduced colocalisation of PIP₃ with Rab14 was only partially rescued by overexpression of PINK1 and was not PINK1 kinase-dependent (Fig. S3).

Interestingly, a time lag for PIP₃ localisation to the Golgi after PDGF, EGF and insulin stimulation has been described (Ebner et al., 2017). We sought to determine whether this was also apparent in response to IGF-1 and, furthermore, whether this was regulated by PINK1. Our results show that following short-term IGF-1 stimulation (10 min) the colocalisation of PIP₃ with giantin was low in all cell lines (PINK1^{+/+} 17.6%, PINK1^{-/-} 10%, hPINK1_{res} 15.7%, hPINK1_{TKD} 17.4%) (Fig. 5C). However, longer-term stimulation with IGF-1 (60 min) resulted in a moderate increase in the colocalisation of PIP₃ with giantin in wild-type and hPINK1_{res} cells (26% and 20%, respectively), but not in PINK1^{-/-} and hPINK1_{TKD} MEFs (13.9% and 11.5%, respectively) (Fig. 5C). Taken together, these results indicate that PIP₃ localises to the medial-Golgi under normal growth conditions, and that PINK1 kinase activity plays a key role in regulating the localisation of PIP₃ to the medial-Golgi.

PINK1 colocalises with PIP₃ and protects against Golgi fragmentation with Akt dependency

PINK1 has been reported to have a dynamic subcellular localisation including within the cytosol (Dagda et al., 2009, 2014; Dickey and Strack, 2011; Fedorowicz et al., 2014; Ries et al., 2006; Steer et al., 2015; Xiong et al., 2009), with increased localisation of PINK1 at the mitochondria when mitochondria are depolarised (Kane et al., 2014; Kazlauskaitė et al., 2014; Kondapalli et al., 2012; Koyano et al., 2014; Matsuda et al., 2010; Shiba-Fukushima et al., 2012; Vincow et al., 2013; Ziviani et al., 2010). Due to our discovery that PINK1 could modulate PIP₃ localisation both at the plasma membrane and the medial-Golgi in a PINK1-kinase dependent fashion, we investigated the possible colocalisation of overexpressed His-tagged hPINK1_{res} and PIP₃. Our results reveal a clear colocalisation of His-tagged hPINK1_{res} and PIP₃ (Fig. 6A).

Golgi fragmentation is a known characteristic of PD neuropathology (Fujita et al., 2006; Gosavi et al., 2002; Rendon et al., 2013). Because of our findings that PINK1 could colocalise with PIP₃ and regulate levels of PIP₃ in the medial-Golgi, we were interested to determine whether PINK1 regulated Golgi morphology. We employed both giantin and GM130 (also known as GOLGA2) to examine Golgi morphology and we found that PINK1^{-/-} MEFs demonstrated significant levels of Golgi fragmentation during serum deprivation (Fig. 6B). Notably, Golgi fragmentation was rescued by hPINK1 overexpression and was PINK1 kinase-dependent (Fig. 6B). We further showed that this aberrant Golgi morphology was not altered by short-term (10 min) or long-term (60 min) stimulation with IGF-1 in the absence of PINK1 kinase activity. We next hypothesised that increased PINK1 kinase-induced localisation of PIP₃ in the medial-Golgi protected against Golgi fragmentation via Akt activation. To investigate this, we treated hPINK1_{res} MEFs with the selective Akt inhibitor MK2206 (Yap et al., 2011). Low concentrations (1 μM) of MK2206 prevented Akt activation with no significant effect on cell survival in hPINK1_{res} MEFs (Fig. 6C). Furthermore, PINK1-induced protection from Golgi fragmentation, evident in hPINK1_{res} MEFs, was completely blocked by Akt inhibition (Fig. 6D). Taken together, these results indicate that PINK1 kinase activity promotes Akt activity, that it dynamically regulates its major activating lipid PIP₃, particularly at the medial-Golgi, and that PINK1 kinase-dependent Akt activation protects against Golgi fragmentation.

PINK1 can modulate the cellular levels of PIP₃ and PIP₂

Finally, we were interested to determine whether PINK1 could directly regulate total cellular phosphatidylinositol (PI) levels. Using advanced mass spectrometry approaches (Kielkowska et al., 2014) we measured total levels of phosphatidylinositol (PI), phosphatidylinositol phosphate (PIP), PIP₂ and PIP₃ in wild-type and PINK1-modified MEFs under normal growth conditions, following 24 h serum deprivation and upon 10-min IGF-1 stimulation. PIP₃ levels were significantly reduced in PINK1^{-/-} MEFs in normal growth medium (but not in serum deprivation conditions or in response to IGF-1 stimulation); this was partially rescued by hPINK1_{res} but was not kinase-dependent (Fig. S4B). PIP₂ levels were significantly lower in PINK1^{-/-} cells in response to IGF-1 stimulation (but not in normal growth medium or under serum deprivation conditions) and this was partially rescued by hPINK1_{res} but was not kinase-dependent (Fig. S4C). There were no significant differences in levels of PI and PIP between PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} cells (Fig. S4D,E). Thus, PINK1 kinase activity can selectively modulate the total cellular




Fig. 5. See next page for legend.

Fig. 5. PIP₃ localisation is PINK1 kinase-dependent. (A) Representative confocal images showing PIP₃ localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs. Serum-starved cells were stimulated with 10 ng/ml IGF-1 for the indicated times, or pre-incubated with 10 μM LY294002 and subsequently stimulated with 10 ng/ml IGF-1, and immunostained for PIP₃ (green) and DAPI (blue) (*n*=3 biological replicates). Scale bar: 10 μm. (B) Representative confocal images showing PIP₃ localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs, which were grown in DMEM-Hi supplemented with 10% FBS, and immunostained for PIP₃ (green) and giantin (red). Scale bar: 10 μm. The accompanying histogram shows the proportion of colocalisation of PIP₃ and giantin in each cell type (*n*=3 biological replicates). (C) Representative confocal images showing PIP₃ localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs. Serum-starved cells were stimulated with 10 ng/ml IGF-1 for the indicated times, and immunostained for PIP₃ (green) and giantin (red). Scale bar: 10 μm. The accompanying histogram shows the proportion of colocalisation PIP₃ and giantin (*n*=3 biological replicates). Data are presented as mean±s.e.m. **P*<0.05, ***P*<0.01 with respect to PINK1^{+/+} MEFs and hPINK1_{res} MEFs, ####*P*<0.0001 with respect to PINK1^{-/-} MEFs (one-way ANOVA).

levels of PIP₂ and PIP₃ under certain conditions. However, this does not appear to directly underpin the regulation of normal and IGF-1-induced subcellular localisation of PIP₃ by PINK1 kinase activity.

DISCUSSION

The serine-threonine kinase PINK1 has been extensively investigated since its discovery as an autosomal recessive PD-causing gene (Valente et al., 2004). PINK1 activates and interacts with PI3-kinase–Akt signalling to induce cell survival, mitochondrial integrity and stress resistance (Akundi et al., 2012; Boonying et al., 2019; Contreras-Zárate et al., 2015; Ellis et al., 2013; Hauser et al., 2017; Maj et al., 2010; Mei et al., 2009; Murata et al., 2011; O’Flanagan et al., 2015; O’Flanagan and O’Neill, 2014; Sánchez-Mora et al., 2012; Soutar et al., 2018). Notably, Akt activity is significantly reduced in both *in vitro* PD models and human dopaminergic substantia nigral neurons in individuals with PD (Malagelada et al., 2008; Timmons et al., 2009). However, the mechanisms by which Akt activation becomes impaired due to loss of PINK1 function in PD are unclear. In this study, we show that PINK1 is a primary upstream activator of Akt during normal growth, and constitutively activates Akt in the absence of growth factors. We reveal for the first time that promotion of Akt activation by PINK1 is PINK1 kinase-dependent, and that PINK1 kinase activity enhances Akt recruitment to the plasma membrane during normal growth and in response to IGF-1. We show that PINK1 regulates the phosphorylation of PI3-kinase p85, colocalises with its product PIP₃, the lipid essential for Akt membrane recruitment, vital for Akt activation (Manning and Toker, 2017). Furthermore, we show that PINK1 dynamically increases PIP₃ levels at the plasma membrane and Golgi in response to short- and longer-term IGF-1 stimulation, respectively, and during normal growth. We demonstrate that PINK1 deletion induces Golgi fragmentation, a known characteristic of PD neuropathology. Importantly, we show that PINK1 overexpression restores normal Golgi morphology and that this depends on activation of PINK1 kinase and of Akt. Together these data provide novel insights into mechanisms by which loss of PINK1 function causes Akt signalling defects in PD.

Full Akt activation requires mTORC2-induced phosphorylation of Akt at Ser⁴⁷³ in the C-terminal hydrophobic motif (Alessi et al., 1996; Sarbassov et al., 2005; Stokoe et al., 1997) and PDK-1 phosphorylation of Akt at Thr³⁰⁸ in the activation loop (Calleja et al., 2007; Stokoe et al., 1997; for review see Manning and Toker, 2017). MEFs derived from PINK1^{-/-} mice display impaired IGF-1-dependent Akt phosphorylation at both Ser⁴⁷³/Thr³⁰⁸ activating

residues (Akundi et al., 2012). The present study is the first to reveal that phosphorylation at both Akt-activating residues in PINK1^{-/-} MEFs can be rescued by PINK1 overexpression and is PINK1 kinase-dependent. Our results further indicate that the impact of PINK1 appears to be more prominent for phosphorylation at Ser⁴⁷³ than Thr³⁰⁸. Notably, the activation of Akt is extremely diminished in the absence of Ser⁴⁷³ phosphorylation (Alessi et al., 1996; Yang et al., 2002). One recent study concluded that PIP₃ activation of Akt is predominantly due to recruitment of Akt to PIP₃ in membranes to facilitate PDK1 and mTORC2 catalysed Akt phosphorylation (Chu et al., 2018). However in contrast, another recent study found that PIP₃ binding allosterically activates Akt and that dissociation from PIP₃ is rate limiting for Akt dephosphorylation (Ebner et al., 2017). It is thus possible that our results indicate that PINK1 inhibits PIP₃ dissociation that favours Akt phosphorylation at Ser⁴⁷³ over Thr³⁰⁸ by more effectively blocking Ser⁴⁷³ dephosphorylation. The more pronounced effect of PINK1 on Ser⁴⁷³ phosphorylation may be further due to regulation of a number of properties reported for Ser⁴⁷³ phosphorylation (Chu et al., 2018; Lučić et al., 2018; Manning and Toker, 2017) or possible regulation by mTORC2 (Murata et al., 2011).

Furthermore, our results demonstrate that PINK1 can constitutively activate Akt, increasing phosphorylation at both activating residues, even in the absence of growth factors, and that this is dependent on PINK1 kinase activity. This places PINK1 kinase as a primary upstream activator of Akt, in agreement with studies which showed that PINK1 is necessary for maximal responses of Akt to growth factors (Akundi et al., 2012; Contreras-Zárate et al., 2015; Ellis et al., 2013; Maj et al., 2010; Manning and Toker, 2017; Mei et al., 2009; Murata et al., 2011; Sánchez-Mora et al., 2012), preventing apoptosis, promoting cell survival and protecting against several cell stressors (Akundi et al., 2012; Contreras-Zárate et al., 2015; Murata et al., 2011; Sánchez-Mora et al., 2012). Importantly, it has been shown that PINK1 mRNA expression is induced by FOXO3a, a major stress-resistant transcription factor, which is upregulated in the absence of Akt activation when growth factors and nutrients are absent (Mei et al., 2009). Our results showing that PINK1 can activate Akt constitutively when growth factors and nutrients are absent may indicate a role for this pathway in the short-term protection necessary to sustain cells until growth factors are available. The PI3-kinase–Akt pathway is intimately linked with mitochondrial respiration, prevention of mitochondrial apoptosis, and metabolic rewiring via enhanced glycolysis, including in cancer cells (for review see O’Flanagan and O’Neill, 2014). PINK1 has been most studied as a key regulator of mitochondrial health, particularly in the regulation of mitophagy via the PINK1/parkin mitophagy pathway (Harper et al., 2018; Kane et al., 2014; Kawajiri et al., 2010; Kazlauskaitė et al., 2014; Kondapalli et al., 2012; Koyano et al., 2014; Matsuda et al., 2010; Pilsl and Winklhofer, 2012; Soutar et al., 2018; Vincow et al., 2013; Youle and Narendra, 2011; Youle and van der Bliek, 2012). Previous studies showed that inhibition of Akt with MK2206 blocks the PINK1/parkin pathway (Hauser et al., 2017; McCoy et al., 2014). More recent studies show that Akt signalling regulates PINK1-dependent mitophagy (Soutar et al., 2018). In these contexts, Akt activation was placed upstream of PINK1 and it was recognised that the reciprocal regulation of PINK1 by Akt and Akt by PINK1 is important in mitophagy regulation (Soutar et al., 2018).

Our major aim was to determine the mechanism by which PINK1 promotes Akt activation. We hypothesised that PINK1 may induce both PDK-1 phosphorylation of Akt at Thr³⁰⁸ and




Fig. 6. See next page for legend.

Fig. 6. PINK1 colocalises with PIP₃ and protects against Golgi fragmentation in an Akt-dependent manner.

(A) Representative confocal images showing PIP₃ colocalising with His-tagged PINK1 in hPINK1_{res} MEFs, which were grown in DMEM-Hi supplemented with 10% FBS, and stained with antibodies to PIP₃ (green) and His (red) (*n*=3 biological replicates). Scale bar: 10 µm. (B) Representative confocal images showing GM130 and giantin localisation in PINK1^{+/+}, PINK1^{-/-}, hPINK1_{res} and hPINK1_{TKD} MEFs. Serum-starved cells were stimulated with 10 ng/ml IGF-1 for the indicated times, and immunostained for GM130 (green) and giantin (red) (*n*=3 biological replicates). Scale bar: 10 µm. (C) Representative immunoblot analysis showing phosphorylation of Akt at Ser⁴⁷³ and Thr³⁰⁸ in hPINK1_{res} MEFs incubated with 1 µM MK2206 for the indicated times. Histogram depicting cell survival as measured by crystal violet staining in hPINK1_{res} MEFs incubated with 1 µM MK2206 for the indicated times. Data are presented as mean±s.e.m. (D) Representative confocal images showing GM130 and giantin localisation in hPINK1_{res} MEFs. Serum-starved cells were incubated with 1 µM MK2206 for the indicated times, and immunostained for GM130 (green) and giantin (red) (*n*=3 biological replicates). Scale bar: 10 µm.

mTORC2-induced phosphorylation of Akt at Ser⁴⁷³ (Alessi et al., 1996; Sarbassov et al., 2005; Stokoe et al., 1997). Interestingly, previous studies showed that PINK1 can induce mTORC2 activation of Ser⁴⁷³ in the absence of Thr³⁰⁸ phosphorylation. This was indicated to be via Rictor, and to occur independently of PI3-kinases (Murata et al., 2011). In contrast, we found that PINK1-induced increased phosphorylation of Akt at both Ser⁴⁷³ and Thr³⁰⁸ residues was not associated with altered levels of active PDK1 or of Rictor. The discrepancies between these studies regarding the mechanisms by which PINK1 can activate Akt may be due to cell- or agonist-specific effects.

Dynamic, rapid, and transient agonist-induced accumulation of Akt at the plasma membrane is essential for growth factor- and agonist-induced Akt activation (for review see Manning and Toker, 2017), and can be monitored by GFP–Akt–PH transfection (Calleja et al., 2007; Ebner et al., 2017; Meyer et al., 2012). Our results provide novel data showing that PINK1 significantly accelerates this recruitment of GFP–Akt–PH and GFP–Akt to the plasma membrane with PINK1 kinase-dependency, both in normal growth media and in response to shorter-term IGF-1 stimulation. The recruitment of Akt to the plasma membrane occurs via its PH domain and relies predominantly on increased, localised and rapid production of PIP₃ (Calleja et al., 2007; Manning and Toker, 2017). These initial rapid plasma membrane and subsequent longer-term endomembrane localisations of PIP₃, particularly in the Golgi and ER, in response to agonists and/or growth factors are critical determinants of compartment-specific Akt activation (Ebner et al., 2017; Jethwa et al., 2015; Manning and Toker, 2017; Sato et al., 2003). These results drew us to explore the possibility that PINK1 may regulate the production of PIP₃ within the plasma membrane and endomembranes. We show that PINK1 kinase activity accelerates the production of PIP₃ towards the plasma membrane in response to short-term stimulation by IGF-1 (2 min and 10 min). Interestingly, several cells expressing hPINK1_{res} had distinct areas of PIP₃ immunoreactivity near the plasma membrane, even in the presence of the PI3-kinase inhibitor. There may be both PI3-kinase dependent and independent mechanisms responsible for the PINK1-induced PIP₃ increases. The changes in PI3-kinase phosphorylation indicate that activation of Akt by PINK1 may be mechanistically linked to the p85 regulatory subunit. However, p85α and p85β have many functions that do not involve PI3-kinase activation, for example, p85α can regulate PTEN (Chagpar et al., 2010; Cheung et al., 2015; Rabinovsky et al., 2009) and the PI3-kinase p110α subunit catalytic activity can occur independently of p85α and p85β (Thorpe et al., 2017; Tsolakos et al., 2018).

We further show that His-tagged PINK1 displays a very strong co-localisation with PIP₃, throughout the cell during normal growth, further supporting PINK1's function as a regulator of PIP₃ within both plasma- and endo-membranes. A previous study using spatio-temporal examination of PIP₃ production in living cells, following ligand stimulation, demonstrated that PIP₃ levels increase to a larger extent in endomembranes (ER and Golgi) than at the plasma membrane (Sato et al., 2003). In agreement, we show that PIP₃ is predominantly localised in the perinuclear region during normal growth. We performed a detailed analysis to determine the endomembrane localisation of PIP₃ and demonstrate a strong selective co-localisation of PIP₃ with giantin in the medial-Golgi compartment. Importantly, we further show that PINK1 deletion significantly and selectively reduces the localisation of PIP₃ to the medial-Golgi during normal growth, and moderately in response to longer-term IGF-1 stimulation (60 min), and show that this is PINK1 kinase-dependent. In agreement with our study, a time-lag for PIP₃ localisation to the Golgi has been shown following PDGF, EGF and insulin stimulation of Akt in HeLa and MCF-7 cells (Ebner et al., 2017). The Golgi plays a pivotal role in the compartmentalisation of cell signalling initiating at the plasma membrane (Peng et al., 2014). Our results thus indicate a new role for PINK1 kinase activity in the regulation of PIP₃ responses in the plasma membrane, Golgi and endomembranes, which are known to be important for both compartmentalised and temporal regulation of Akt substrate phosphorylation (Ebner et al., 2017; Jethwa et al., 2015; Manning and Toker, 2017; Sato et al., 2003). Furthermore, PIP₃ generation *in situ*, primarily in the Golgi and ER, has been shown to depend on endocytosis of activating receptor tyrosine kinases. Interestingly, in this respect it has been reported that PINK1 deficiency disturbs the intracellular localisation of the IGF-1 receptor (Contreras-Zárate et al., 2015).

Although we did not detect Akt in the Golgi network we do think there is potential that it is also present here. The main tools employed were GFP–Akt and GFP–Akt–PH constructs, and we do not see any Golgi localisation with either of these. However, these constructs may favour the plasma membrane and the concentration of Akt may be higher at the plasma membrane than in endomembrane compartments in these PINK1-modified MEFs. Thus, the availability of more sensitive tools such as improved Akt-specific antibodies may uncover Akt in the Golgi, and the endosome–ER–Golgi network.

In healthy cells, the Golgi complex is a ribbon-like structure made up of flattened, parallel cisternae that are interconnected in the perinuclear region (Nakagomi et al., 2008), as we observe in wild-type MEFs. Numerous studies have shown that during cell stress or apoptotic cell death, Golgi stacks disassemble into tubulovesicular clusters, a process known as fragmentation of the Golgi complex (Alvarez-Miranda et al., 2015; Chiu et al., 2002; Fan et al., 2008; Lane et al., 2002; Machamer, 2003). Golgi fragmentation has been reported in nigral neurons in postmortem samples of brain from individuals with PD (Fujita et al., 2006) and in *in vitro* PD models (Gosavi et al., 2002; Rendon et al., 2013). Furthermore, bioinformatics modelling has linked stress-induced Golgi fragmentation to a number of neurodegenerative processes (Alvarez-Miranda et al., 2015). We reveal for the first time that PINK1 deletion causes significant Golgi fragmentation, and importantly, we show that this is prevented by PINK1 overexpression and is dependent on PINK1 kinase activity. This is a significant new function for PINK1 and furthermore is linked mechanistically to impaired Akt signalling caused by PINK1 deletion. Thus, we show that Akt inhibition in cells overexpressing

PINK1 prevents the ability of PINK1 to protect against Golgi fragmentation. Interestingly, inhibition of PI(4,5)P₂ (PIP₂) synthesis in GH3 cells has been reported to lead to Golgi fragmentation, linking phosphoinositides with the structural integrity of the Golgi apparatus (Siddhanta et al., 2003).

In this study, we demonstrate that impaired activation of Akt, via loss of PINK1 kinase function, as occurs in PD, centres on defects in PIP₃ regulation upstream of Akt activation. Our mass spectrometry analysis showed that total levels of PIP₃ and PIP₂, but not PIP and PI, lipids were modulated by PINK1 deletion in some contexts, but not regulated in a PINK1 kinase-dependent manner. This suggests that PINK1 kinase regulates selective membrane pools of PIP₃ rather than total PIP₃ levels. It is important to note that several risk genes for PD regulate the PI3-kinase–Akt signalling axis, including *parkin* (*PRKN*) (Fallon et al., 2006; Gupta et al., 2017), *DJ-1* (*PARK7*) (Jaramillo-Gómez et al., 2015; Kim et al., 2011; Zhang et al., 2016), *LRRK2* (Chuang et al., 2014; Ohta et al., 2011) and *SNCA* (Seo et al., 2002). Importantly, defects in Akt signalling occur in nigral neurons in the brain of individuals with PD (Malagelada et al., 2008; Timmons et al., 2009), drawing attention to the relevance of targeting this vital survival and metabolic system for neuroprotection in PD. Phosphoinositide–protein interactions are at the hub of both Akt and other major signalling axes and play integral roles in vesicular trafficking. These are key systems known to be regulated by PD risk genes (Cao et al., 2017; Krebs et al., 2013; Vanhauwaert et al., 2017) and known to become impaired in PD (Kutateladze, 2010; Wenk and De Camilli, 2004). Our study provides new mechanistic insights for a modulation of the core PIP₃–Akt regulatory machinery by PINK1 kinase activity, presenting a novel mechanism that may underlie impaired activation of the vital Akt signalling machinery in PD. This draws attention to the integration of phosphoinositide and protein networks in the understanding and therapeutic targeting of key systems, including Akt, that become defective in the neurodegenerative processes underlying PD.

MATERIALS AND METHODS

Generation of PINK1^{-/-} mice and derived MEF cell lines

The cell lines used in these experiments are mouse embryonic fibroblast (MEF) cells, as previously employed and described (Glasl et al., 2012; Morais et al., 2009; O'Flanagan et al., 2015). PINK1^{-/-} knockout and PINK1^{+/-} heterozygous knockout mice were generated by Wolfgang Wurst and Daniela Vogt-Weisenhorn (Helmholtz Center, Munich, Germany) and immortalised MEFs were generated as previously described (Morais et al., 2009). In brief, PINK1^{+/-} mice were interbred to generate mutant mice and wild-type littermate controls. Embryonic day 13 mice were dissected, heads and red organs removed and used for genotyping. The rest of the bodies were chopped up in cell culture dishes containing Dulbecco's modified Eagle's medium supplied with 50% foetal bovine serum and 1% penicillin/streptomycin. Cultures were expanded and serum decreased to 10% foetal bovine serum after the attainment of consistent growth. Afterward cultures were immortalised by transfection with simian virus 40 (SV40) large T-antigen. PINK1^{-/-} MEFs were stably transfected with a plasmid containing human PINK1 (hPINK1 construct Origene, Rockville, MD, USA), and the triple kinase-dead hPINK1_{K219A/D362A/D384A} (hPINK1_{TKD}) mutants using site-directed mutagenesis (Stratagene, Santa Clara, CA, USA). The triple kinase-dead mutation for PINK1 is not known to affect the stability or conformation of the PINK1 protein (Pridgeon et al., 2007). Cells were routinely monitored for mycoplasma and bacterial or yeast contaminations.

RT-PCR

PINK1 deletion or expression was confirmed in MEF cell lines employed in this study using RNA extraction and RT-PCR analysis (Fig. S4A). RNA was extracted using the PureLink RNA Mini Kit (Thermo Fisher Scientific)

according to the instructions of the manufacturer. cDNA synthesis was performed with the QuantiTect reverse transcription kit (Qiagen) using 1 µg of RNA. The primers and conditions used for RT-PCR are shown in Table S1, this was performed using the GoTaq G2 Green Master Mix kit (Promega).

Cell culture and stimulation or inhibition of the PI3-kinase–Akt pathway

MEFs were cultured in Dulbecco's modified Eagle's medium: high glucose (DMEM-Hi), supplemented with 10% foetal bovine serum (FBS) and 2 mM L-glutamine. Cells were cultured at 37°C in a humidified incubator supplemented with 5% CO₂. In IGF-1 stimulation experiments, cells were plated overnight with complete media, followed by incubation with serum-free DMEM-Hi for 24 h. After 24 h, 10 ng/ml IGF-1 (Peprotech, 100-11) was added at the specified time-points (2, 10 or 60 min). In experiments for inhibition of PI3-kinases, cells were plated overnight with complete media, incubated with serum-free DMEM-Hi for 24 h, followed by incubation with 10 µM LY294002 for 30 min and subsequent stimulation with 10 ng/ml IGF-1 for 10 min. In experiments for MK2206 inhibition, cells were plated overnight with complete media, serum-deprived for 24 h and then incubated with 1 µM MK2206 for 1 h or 4 h. For Lysotracker and PIP₃ colocalisation analysis (Fig. 3), 75 nM of Lysotracker (Invitrogen) was added to the cells in culture for 1 h before fixation with 3% PFA for immunocytochemistry. BE(2)-M17 cells, transduced with PINK1 shRNA (PINK1A8, PINK1C2) or with control shRNA (Control 1, Control 2), were kindly provided by Mark Cookson and Alexandra Beilina (National Institute on Aging, Bethesda, MD, USA) and were transduced and cultured as previously described (Sandebring et al., 2009).

Plasmids

The GFP–Akt–PH construct was kindly provided by Martin Lowe (University of Manchester, Manchester, UK). pEGFP–Akt was deposited by Julian Downward (Addgene plasmid #39531) (Watton and Downward, 1999). MEFs were seeded in 24-well plates to be 70% confluent the following day. Cells were then transfected with GFP–Akt–PH or GFP–Akt using Lipofectamine (Invitrogen) as recommended by the manufacturer's instructions.

Western immunoblotting

Primary antibodies raised against the following were used: Akt (1:1000; 9272), Akt 1 (1:1000; 2938), Akt 2 (1:1000; 3063), Akt 3 (1:1000; 8018), P-Akt pSer⁴³⁷ (1:500; 4060), P-Akt pThr³⁰⁸ (1:500; 9275), P-PDK1^{Ser241} (1:500; 3061), P-PI3-kinase p85^{Tyr458}/p55^{Tyr199} (1:500; 4228), PI3-kinase p85α (1:1000; 4257), PTEN (1:500; 9552), P-PTEN^{Ser380} (1:500; 9551), RICTOR (1:500; 2114) (all from Cell Signaling Technology), PI3-kinase p110α (1:500; BD Transduction Laboratories, 611399), β-actin (1:16,000; Sigma-Aldrich, A5441). Primary antibodies were detected using horseradish peroxidase (HRP)-conjugated isotype-specific anti-rabbit IgG or anti-mouse IgG (1:1000; DAKO, Cambridgeshire, UK) secondary antibodies.

Western immunoblotting was carried out as described previously (Griffin et al., 2005; Moloney et al., 2010; O'Flanagan et al., 2015). Briefly, proteins were extracted, separated by SDS-PAGE (20 µg/lane) and transferred electrophoretically to nitrocellulose membranes using a wet transfer apparatus and transfer buffer consisting of 48 mM Tris base, 39 mM glycine and 20% ethanol. After blocking for 1 h in 5% milk or 30 min in 5% bovine serum albumin (phospho antibodies), cells were incubated in primary antibody solutions overnight at 4°C. The blot underwent three 10-min washes in 1× TBX-T prior to secondary antibody incubation. Cells were incubated in secondary antibody solution for 1 h at room temperature followed by three 5-min washes in 1× TBS-T. Immunoreactive proteins were detected with enhanced chemiluminescence (Amersham Biosciences, Little Chalfont, UK). All quantifications are illustrated by histograms that represent the densitometry of each protein normalised to β-actin for an *n*=3, as determined by ImageJ software.

Immunofluorescence and confocal microscopy

Primary antibodies raised against the following were used: phosphatidylinositol (3,4,5)-trisphosphate (1:150; Tebu-Bio, 117Z-P345B), giantin (1:300; kindly provided by Martin Lowe, University of Manchester), GM130 (1:4000; BD

Biosciences, 610822), GRP-78-BIP (1:800; Abcam, Ab21685), His (1:400; Abcam, 9108) Rab11a (1:100; Zymed, 715300), Rab14 (1:500; Sigma-Aldrich, R0656) and TGN46 (1:500; Serotek UK, AHP500). Primary antibodies were detected using Cy3-conjugated anti-rabbit IgG (1:400; Jackson ImmunoResearch Laboratories, 711-165-152) or Alexa Fluor 488-conjugated anti-mouse IgG (1:400; Invitrogen, A11001) secondary antibodies.

Culture medium was removed from each of the wells. Cells were washed with 1× PBS between each of the following steps: fixation in 0.5 ml 3% paraformaldehyde (PFA) for 15 min at room temperature, quenching in 1 ml of 50 mM NH₄Cl/PBS for 15 min, permeabilisation in 1 ml buffer (0.05% saponin/PBS, 0.2% BSA/PBS) for 5 min. Coverslips were transferred to a humid box and primary antibodies were added at appropriate dilutions in 5% BSA/PBS. Primary antibodies were incubated for 2 h at room temperature. Then cells were washed twice in 1× PBS. Cells were incubated in secondary antibody solutions in 5% BSA/PBS, as well as DAPI/PBS (1:10,000) for 1 h at room temperature. Cells were washed twice with 1× PBS for 5 min. Coverslips were mounted onto microscope slides using Mowiol mounting media. Cells were dried overnight and fluorescence images were acquired using Zeiss LSM 510 Meta confocal microscope fitted with a 63×/1.4 plan apochromat lens (Jena, Germany).

For GFP-Akt-PH analysis, each experiment was performed in duplicate. For the two coverslips per condition >200 cells were counted. The threshold of intensity used was fluorescence in the cytosol as the baseline and any fluorescence intensity level above that at the plasma membrane (PM) was judged as an accumulation at the PM. To quantify the localisation of Akt at the PM the total number of transfected cells and the number of cells with Akt at the plasma membrane were counted (determined as described above). From these values the percentage of cells with Akt at the PM was then calculated for $n=3$ and the representative histogram generated in Prism (GraphPad). To determine fluorescence intensity at the plasma membrane a line plot was drawn through the cell using the plot profile analysis in Carl Zeiss Zen 2.1 image analysis software, as described previously (Lindsay and McCaffrey, 2009). The x -axis represents distance along the line and the y -axis is the pixel intensity. Pearson's colocalisation coefficient was calculated using Zeiss ZEN 2009 software as described previously (Lindsay et al., 2013).

Mass spectrometry

Mass spectrometry was used to measure inositol lipid levels essentially as previously described (Clark et al., 2011), using a QTRAP 4000 (AB Sciex) mass spectrometer and employing the lipid extraction and derivitisation method described for cultured cells, with the modification that 10 ng C17:0/C16:0 PtdIns(3,4,5)P₃ internal standard (ISD) and 10 ng C17:0/C16:0 PtdIns ISD were added to primary extracts, and that final samples were dried in a Speedvac concentrator rather than under liquid N₂. Measurements were conducted in duplicate for three separate experiments, on 3×10⁵ cells per sample. PIP, PIP₂ and PIP₃ response ratios were calculated by dividing PIP, PIP₂ and PIP₃ response areas by the corresponding response areas of PIP₂ (for PIP and PIP₂) and PIP₃ (PIP₃ only) ISD in each sample. PIP, PIP₂, and PIP₃ responses were normalised to PI response ratio to account for any cell input variability.

Crystal Violet staining

Crystal Violet staining was used for assaying cell survival in response to treatment with MK2206. Cells were fixed with 4% PFA for 20 min, followed by staining with 0.05% Crystal Violet in 20% ethanol for 30 min. Cells were washed with dH₂O and let to dry overnight and images were acquired using the Odyssey imaging system.

Statistical analysis

All data were analysed using GraphPad Prism. Data are expressed as means ±s.e.m. Statistical analysis was carried out using one-way ANOVA, followed by a post-hoc Tukey test if the ANOVA indicated significance. Differences were considered significant at $P<0.05$.

Acknowledgements

We are thankful to Bart De Strooper (VIB Center for the Biology of Disease, VIB, Leuven, Belgium and Center for Human Genetics and LIND, K.U. Leuven, Leuven, Belgium) and Vanessa Morais (Instituto de Medicina Molecular Lisboa, Portugal),

for providing us with PINK1-modified mouse embryonic fibroblast cells. We are grateful to Mark Cookson and Alexandra Beilina (National Institute on Aging, Bethesda, MD, USA) for providing us with BE(2)-M17 cells transduced with control and PINK1 shRNA. The Molecular Cell Biology group, UCC, provided access to a Zeiss 510 confocal microscope, funded by an SFI Programme Grant to Mary W. McCaffrey.

Competing interests

The authors declare no competing or financial interests.

Author contributions

Conceptualization: R.M.F., A.M.S., C.O.; Methodology: R.M.F., A.L., A.M.S., C.O.; Validation: R.M.F.; Formal analysis: R.M.F.; Investigation: R.M.F., K.E.A., P.T.H.; Resources: A.L., A.M.S., C.O.; Writing - original draft: R.M.F.; Writing - review & editing: R.M.F., A.L., K.E.A., P.T.H., A.M.S., C.O.; Visualization: R.M.F.; Supervision: A.M.S., C.O.; Project administration: R.M.F., A.M.S., C.O.; Funding acquisition: R.M.F., A.M.S., C.O., K.E.A., P.T.H.

Funding

This work was funded by the Irish Research Council for Science, Engineering and Technology Government of Ireland Postgraduate Scholarship Programme grant number GOIPG/2015/3467. K.E.A. and P.T.H. are funded by the Biotechnology and Biological Research Council (BBSRC) UK grant number BB/P013384/1.

Supplementary information

Supplementary information available online at <http://jcs.biologists.org/lookup/doi/10.1242/jcs.233221.supplemental>

References

- Akundi, R. S., Zhi, L. and Büeler, H. (2012). PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis. *Neurobiol. Dis.* **45**, 469-478. doi:10.1016/j.nbd.2011.08.034
- Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and Hemmings, B. A. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* **15**, 6541-6551. doi:10.1002/j.1460-2075.1996.tb1045.x
- Alvarez-Miranda, E. A., Sinnl, M. and Farhan, H. (2015). Alteration of Golgi structure by stress: a link to neurodegeneration? *Front. Neurosci.* **9**, 435. doi:10.3389/fnins.2015.00435
- Arena, G. and Valente, E. M. (2017). PINK1 in the limelight: multiple functions of an eclectic protein in human health and disease. *J. Pathol.* **241**, 251-263. doi:10.1002/path.4815
- Arena, G., Gelmetti, V., Torosantucci, L., Vignone, D., Lamorte, G., De Rosa, P., Cilia, E., Jonas, E. A. and Valente, E. M. (2013). PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xL and impairing its pro-apoptotic cleavage. *Cell Death Differ.* **20**, 920-930. doi:10.1038/cdd.2013.19
- Aweida, D., Rudesky, I., Volodin, A., Shimko, E. and Cohen, S. (2018). GSK3- β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. *J. Cell Biol.* **217**, 3698-3714. doi:10.1083/jcb.201802018
- Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malmstrom, S., Stokoe, D., McCormick, F., Feng, J. and Tsichlis, P. (1998). Akt activation by growth factors is a multiple-step process: the role of the PH domain. *Oncogene* **17**, 313-325. doi:10.1038/sj.onc.1201947
- Boonying, W., Joselin, A., Huang, E., Qu, D., Safarpour, F., Iyirhiaro, G. O., Rodriguez Gonzalez, Y., Callaghan, S. M., Slack, R. S., Figeys, D. et al. (2019). Pink1 regulates FKBP5 interaction with AKT/PHLPP and protects neurons from neurotoxin stress induced by MPP⁺. *J. Neurochem.* **150**, 312-329. doi:10.1111/jnc.14683
- Braccini, L., Ciraolo, E., Campa, C. C., Perino, A., Longo, D. L., Tibolla, G., Pregnotato, M., Cao, Y., Tassone, B., Damilano, F. et al. (2015). PI3K-C2 γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. *Nat. Commun.* **6**, 7400. doi:10.1038/ncomms8400
- Calleja, V., Alcor, D., Laguerre, M., Park, J., Vojnovic, B., Hemmings, B. A., Downward, J., Parker, P. J. and Larjani, B. (2007). Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. *PLoS Biol.* **5**, e95. doi:10.1371/journal.pbio.0050095
- Cao, M., Wu, Y., Ashrafi, G., McCartney, A. J., Wheeler, H., Bushong, E. A., Boassa, D., Ellisman, M. H., Ryan, T. A. and De Camilli, P. (2017). Parkinson sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons. *Neuron* **93**, 882-896.e5. doi:10.1016/j.neuron.2017.01.019
- Casamayor, A., Morrice, N. A. and Alessi, D. R. (1999). Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. *Biochem. J.* **342**, 287-292. doi:10.1042/bj3420287
- Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., Kannan, S., Verma, C. S., Dickler, M., Chandrapaty, S. et al. (2016). PDK1-SGK1

- signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3K α inhibition. *Cancer Cell* **30**, 229-242. doi:10.1016/j.ccell.2016.06.004
- Chaggar, R. B., Links, P. H., Pastor, M. C., Furber, L. A., Hawrysh, A. D., Chamberlain, M. D. and Anderson, D. H. (2010). Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. *Proc. Natl. Acad. Sci. USA* **107**, 5471-5476. doi:10.1073/pnas.0908899107
- Cheung, L. W., Walkiewicz, K. W., Besong, T. M., Guo, H., Hawke, D. H., Arold, S. T. and Mills, G. B. (2015). Regulation of the PI3K pathway through a p85 α monomer-homodimer equilibrium. *Life* **4**, e06866. doi:10.7554/eLife.06866
- Chiu, R., Novikov, L., Mukherjee, S. and Shields, D. (2002). A caspase cleavage fragment of p115 induces fragmentation of the Golgi apparatus and apoptosis. *J. Cell Biol.* **159**, 637-648. doi:10.1083/jcb.200208013
- Chu, N., Salguero, A. L., Liu, A. Z., Chen, Z., Dempsey, D. R., Ficarro, S. B., Alexander, W. M., Marto, J. A., Li, Y., Amzel, L. M. et al. (2018). Akt Kinase activation mechanisms revealed using protein semisynthesis. *Cell* **174**, 897-907.e14. doi:10.1016/j.cell.2018.07.003
- Chuang, C.-L., Lu, Y.-N., Wang, H.-C. and Chang, H.-Y. (2014). Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival. *Hum. Mol. Genet.* **23**, 5649-5658. doi:10.1093/hmg/ddu281
- Clark, J., Anderson, K. E., Juvin, V., Smith, T. S., Karpe, F., Wakelam, M. J., Stephens, L. R. and Hawkins, P. T. (2011). Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. *Nat. Methods* **8**, 267-272. doi:10.1038/nmeth.1564
- Contreras-Zárate, M. J., Niño, A., Rojas, L., Arboleda, H. and Arboleda, G. (2015). Silencing of PINK1 inhibits insulin-like growth factor-1-mediated receptor activation and neuronal survival. *J. Mol. Neurosci.* **56**, 188-197. doi:10.1007/s12031-014-0479-0
- Dagda, R. K., Cherra, S. J., III, Kulich, S. M., Tandon, A., Park, D. and Chu, C. T. (2009). Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. *J. Biol. Chem.* **284**, 13843-13855. doi:10.1074/jbc.M808515200
- Dagda, R. K., Pien, I., Wang, R., Zhu, J., Wang, K. Z., Callio, J., Banerjee, T. D., Dagda, R. Y. and Chu, C. T. (2014). Beyond the mitochondrion: cytosolic PINK1 remodels dendrites through protein kinase A. *J. Neurochem.* **128**, 864-877. doi:10.1111/jnc.12494
- Deas, E., Wood, N. W. and Plun-Favreau, H. (2011). Mitophagy and Parkinson's disease: the PINK1-parkin link. *Biochim. Biophys. Acta* **1813**, 623-633. doi:10.1016/j.bbamcr.2010.08.007
- Dickey, A. S. and Strack, S. (2011). PKA/AKAP1 and PP2A/B β regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. *J. Neurosci.* **31**, 15716-15726. doi:10.1523/JNEUROSCI.3159-11.2011
- Ebner, M., Lučić, I., Leonard, T. A. and Yushman, I. (2017). PI(3,4,5)P3 engagement restricts Akt activity to cellular membranes. *Mol. Cell* **65**, 416-431.e6. doi:10.1016/j.molcel.2016.12.028
- Ellis, G. I., Zhi, L., Akundi, R., Bueler, H. and Marti, F. (2013). Mitochondrial and cytosolic roles of PINK1 shape induced regulatory T-cell development and function. *Eur. J. Immunol.* **43**, 3355-3360. doi:10.1002/eji.201343571
- Fallon, L., Belanger, C. M., Corera, A. T., Kontogiannina, M., Regan-Klapisz, E., Moreau, F., Voortman, J., Haber, M., Rouleau, G., Thorarinnsson, T. et al. (2006). A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. *Nat. Cell Biol.* **8**, 834-842. doi:10.1038/ncb1441
- Fan, J., Hu, Z., Zeng, L., Lu, W., Tang, X., Zhang, J. and Li, T. (2008). Golgi apparatus and neurodegenerative diseases. *Int. J. Dev. Neurosci.* **26**, 523-534. doi:10.1016/j.ijdevneu.2008.05.006
- Fedorowicz, M. A., de Vries-Schneider, R. L., Rüb, C., Becker, D., Huang, Y., Zhou, C., Alessi Wolken, D. M., Voos, W., Liu, Y. and Przedborski, S. (2014). Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. *EMBO Rep.* **15**, 86-93. doi:10.1002/embr.201337294
- Fujita, Y., Ohama, E., Takatama, M., Al-Sarraj, S. and Okamoto, K. (2006). Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. *Acta Neuropathol.* **112**, 261-265. doi:10.1007/s00401-006-0114-4
- Glasl, L., Kloos, K., Giesert, F., Roethig, A., Di Benedetto, B., Kühn, R., Zhang, J., Hafen, U., Zerle, J., Hofmann, A. et al. (2012). Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. *Exp. Neurol.* **235**, 214-227. doi:10.1016/j.expneurol.2012.01.002
- Gosavi, N., Lee, H.-J., Lee, J. S., Patel, S. and Lee, S.-J. (2002). Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. *J. Biol. Chem.* **277**, 48984-48992. doi:10.1074/jbc.M208194200
- Griffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R. and O'Neill, C. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *J. Neurochem.* **93**, 105-117. doi:10.1111/j.1471-4159.2004.02949.x
- Gupta, A., Anjomani-Virmouni, S., Koundouros, N., Dimitriadi, M., Choo-Wing, R., Valle, A., Zheng, Y., Chiu, Y.-H., Agnihotri, S., Zadeh, G. et al. (2017). PARK2 Depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-Nitrosylation. *Mol. Cell* **65**, 999-1013.e7. doi:10.1016/j.molcel.2017.02.019
- Hall, B. A., Kim, T. Y., Skor, M. N. and Conzen, S. D. (2012). Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. *Breast Cancer Res. Treat.* **135**, 469-479. doi:10.1007/s10549-012-2161-y
- Haque, M. E., Thomas, K. J., D'Souza, C., Callaghan, S., Kitada, T., Slack, R. S., Fraser, P., Cookson, M. R., Tandon, A. and Park, D. S. (2008). Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. *Proc. Natl. Acad. Sci. USA* **105**, 1716-1721. doi:10.1073/pnas.0705363105
- Harper, J. W., Ordeuau, A. and Heo, J. M. (2018). Building and decoding ubiquitin chains for mitophagy. *Nat. Rev. Mol. Cell Biol.* **19**, 93-108. doi:10.1038/nrm.2017.129
- Hauser, D. N., Mamais, A., Conti, M. M., Primiani, C. T., Kumaran, R., Dillman, A. A., Langston, R. G., Beilina, A., Garcia, J. H., Diaz-Ruiz, A. et al. (2017). Hexokinases link DJ-1 to the PINK1/parkin pathway. *Mol. Neurodegener.* **12**, 70. doi:10.1186/s13024-017-0212-x
- Hers, I., Vincent, E. E. and Tavaré, J. M. (2011). Akt signalling in health and disease. *Cell. Signal.* **23**, 1515-1527. doi:10.1016/j.cellsig.2011.05.004
- Ibrahim, W. W., Abdelkader, N. F., Ismail, H. M. and Khattab, M. M. (2019). Escitalopram ameliorates cognitive impairment in D-galactose-injected ovariectomized rats: modulation of JNK, GSK-3 β , and ERK signalling pathways. *Sci. Rep.* **9**, 10056. doi:10.1038/s41598-019-46558-1
- Jaramillo-Gómez, J., Niño, A., Arboleda, H. and Arboleda, G. (2015). Overexpression of DJ-1 protects against C2-ceramide-induced neuronal death through activation of the PI3K/AKT pathway and inhibition of autophagy. *Neurosci. Lett.* **603**, 71-76. doi:10.1016/j.neulet.2015.07.032
- Jethwa, N., Chung, G. H. C., Lete, M. G., Alonso, A., Byrne, R. D., Calleja, V. and Larjani, B. (2015). Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway. *J. Cell Sci.* **128**, 3456-3465. doi:10.1242/jcs.172775
- Kane, L. A., Lazarou, M., Fogel, A. I., Li, Y., Yamano, K., Sarraf, S. A., Banerjee, S. and Youle, R. J. (2014). PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. *J. Cell Biol.* **205**, 143-153. doi:10.1083/jcb.201402104
- Kawajiri, S., Saiki, S., Sato, S., Sato, F., Hatano, T., Eguchi, H. and Hattori, N. (2010). PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. *FEBS Lett.* **584**, 1073-1079. doi:10.1016/j.febslet.2010.02.016
- Kazlauskaitė, A., Kondapalli, C., Gourlay, R., Campbell, D. G., Ritorto, M. S., Hofmann, K., Alessi, D. R., Knebel, A., Trost, M. and Muqit, M. M. K. (2014). Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. *Biochem. J.* **460**, 127-139. doi:10.1042/BJ20140334
- Kielkowska, A., Niewczas, I., Anderson, K. E., Durrant, T. N., Clark, J., Stephens, L. R. and Hawkins, P. T. (2014). A new approach to measuring phosphoinositides in cells by mass spectrometry. *Adv Biol Regul.* **54**, 131-141. doi:10.1016/j.abior.2013.09.001
- Kim, R. H., Peters, M., Jang, Y., Shi, W., Pintilie, M., Fletcher, G. C., Deluca, C., Liepa, J., Zhou, L., Snow, B. et al. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. *Cancer Cell* **7**, 263-273. doi:10.1016/j.ccr.2005.02.010
- Kim, S. R., Chen, X., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M., Kholodilov, N. and Burke, R. E. (2011). Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. *Ann. Neurol.* **70**, 110-120. doi:10.1002/ana.22383
- Komander, D., Kular, G., Deak, M., Alessi, D. R. and Van Aalten, D. M. (2005). Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding. *J. Biol. Chem.* **280**, 18797-18802. doi:10.1074/jbc.M500977200
- Kondapalli, C., Kazlauskaitė, A., Zhang, N., Woodroof, H. I., Campbell, D. G., Gourlay, R., Burchell, L., Walden, H., Macartney, T. J., Deak, M. et al. (2012). PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. *Open Biol.* **2**, 120080. doi:10.1098/rsob.120080
- Koyano, F., Okatsu, K., Kosako, H., Tamura, Y., Go, E., Kimura, M., Kimura, Y., Tsuchiya, H., Yoshihara, H., Hirokawa, T. et al. (2014). Ubiquitin is phosphorylated by PINK1 to activate parkin. *Nature* **510**, 162-166. doi:10.1038/nature13392
- Krebs, C. E., Karkheiran, S., Powell, J. C., Cao, M., Makarov, V., Darvish, H., Di Paolo, G., Walker, R. H., Shahidi, G. A., Buxbaum, J. D. et al. (2013). The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures. *Hum. Mutat.* **34**, 1200-1207. doi:10.1002/humu.22372
- Kutateladze, T. G. (2010). Translation of the phosphoinositide code by PI effectors. *Nat. Chem. Biol.* **6**, 507-513. doi:10.1038/nchembio.390
- Lane, J. D., Lucocq, J., Pryde, J., Barr, F. A., Woodman, P. G., Allan, V. J. and Lowe, M. (2002). Caspase-mediated cleavage of the stacking protein GRASP65 is required for Golgi fragmentation during apoptosis. *J. Cell Biol.* **156**, 495-509. doi:10.1083/jcb.200110007
- Lee, H. J. and Chung, K. C. (2012). PINK1 positively regulates IL-1 β -mediated signaling through Tollip and IRAK1 modulation. *J. Neuroinflammation* **9**, 271. doi:10.1186/1742-2094-9-271
- Lee, H. J., Jang, S. H., Kim, H., Yoon, J. H. and Chung, K. C. (2012). PINK1 stimulates interleukin-1 β -mediated inflammatory signaling via the positive

- regulation of TRAF6 and TAK1. *Cell. Mol. Life Sci.* **69**, 3301-3315. doi:10.1007/s00018-012-1004-7
- Li, Y., Qiu, L., Liu, X., Hou, Z. and Yu, B. (2017). PINK1 alleviates myocardial hypoxia-reoxygenation injury by ameliorating mitochondrial dysfunction. *Biochem. Biophys. Res. Commun.* **484**, 118-124. doi:10.1016/j.bbrc.2017.01.061
- Lindsay, A. J. and McCaffrey, M. W. (2009). Myosin Vb localises to nucleoli and associates with the RNA polymerase I transcription complex. *Cell Motil. Cytoskeleton* **66**, 1057-1072. doi:10.1002/cm.20408
- Lindsay, A. J., Jollivet, F., Horgan, C. P., Khan, A. R., Raposo, G., McCaffrey, M. W. and Goud, B. (2013). Identification and characterization of multiple novel Rab-myosin Va interactions. *Mol. Biol. Cell* **24**, 3420-3434. doi:10.1091/mbc.e13-05-0236
- Lučić, I., Rathinaswamy, M. K., Truebestein, L., Hamelin, D. J., Burke, J. E. and Leonard, T. A. (2018). Conformational sampling of membranes by Akt controls its activation and inactivation. *Proc. Natl. Acad. Sci. USA* **115**, E3940-e3949. doi:10.1073/pnas.1716109115
- Machamer, C. E. (2003). Golgi disassembly in apoptosis: cause or effect? *Trends Cell Biol.* **13**, 279-281. doi:10.1016/S0962-8924(03)00101-6
- Mackeigan, J. P., Murphy, L. O. and Blenis, J. (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. *Nat. Cell Biol.* **7**, 591-600. doi:10.1038/ncb1258
- Maehama, T. and Dixon, J. E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J. Biol. Chem.* **273**, 13375-13378. doi:10.1074/jbc.273.22.13375
- Maj, M. C., Tkachyova, I., Patel, P., Addis, J. B., Mackay, N., Levandovskiy, V., Lee, J., Lang, A. E., Cameron, J. M. and Robinson, B. H. (2010). Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. *Biochem. Biophys. Res. Commun.* **399**, 331-335. doi:10.1016/j.bbrc.2010.07.033
- Malagelada, C., Jin, Z. H. and Greene, L. A. (2008). RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. *J. Neurosci.* **28**, 14363-14371. doi:10.1523/JNEUROSCI.3928-08.2008
- Manning, B. D. and Toker, A. (2017). AKT/PKB signaling: navigating the network. *Cell* **169**, 381-405. doi:10.1016/j.cell.2017.04.001
- Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J. J., Trudeau, L. E., Burette, Y. et al. (2016). Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation. *Cell* **166**, 314-327. doi:10.1016/j.cell.2016.05.039
- Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y. S., Saiki, S., Kawajiri, S., Sato, F. et al. (2010). PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J. Cell Biol.* **189**, 211-221. doi:10.1083/jcb.200910140
- McCoy, M. K., Kaganovich, A., Rudenko, I. N., Ding, J. and Cookson, M. R. (2014). Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. *Hum. Mol. Genet.* **23**, 145-156. doi:10.1093/hmg/ddt407
- Mei, Y., Zhang, Y., Yamamoto, K., Xie, W., Mak, T. W. and You, H. (2009). FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. *Proc. Natl. Acad. Sci. USA* **106**, 5153-5158. doi:10.1073/pnas.0901104106
- Meyer, R., D'alessandro, L. A., Kar, S., Kramer, B., She, B., Kaschek, D., Hahn, B., Wrangborg, D., Karlsson, J., Kvarnstrom, M. et al. (2012). Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration. *Front. Physiol.* **3**, 451. doi:10.3389/fphys.2012.00451
- Moloney, A. M., Griffin, R. J., Timmons, S., O'Connor, R., Ravid, R. and O'Neill, C. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. *Neurobiol. Aging* **31**, 224-243. doi:10.1016/j.neurobiolaging.2008.04.002
- Morais, V. A., Verstreken, P., Roethig, A., Smet, J., Snellinx, A., Vanbrabant, M., Haddad, D., Frezza, C., Mandemakers, W., Vogt-Weisenhorn, D. et al. (2009). Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. *EMBO Mol. Med.* **1**, 99-111. doi:10.1002/emmm.200900006
- Moult, P. R., Cross, A., Santos, S. D., Carvalho, A.-L., Lindsay, Y., Connolly, C. N., Irving, A. J., Leslie, N. R. and Harvey, J. (2010). Leptin regulates AMPA receptor trafficking via PTEN inhibition. *J. Neurosci.* **30**, 4088-4101. doi:10.1523/JNEUROSCI.3614-09.2010
- Murata, H., Sakaguchi, M., Jin, Y., Sakaguchi, Y., Futami, J., Yamada, H., Kataoka, K. and Huh, N. H. (2011). A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. *J. Biol. Chem.* **286**, 7182-7189. doi:10.1074/jbc.M110.179390
- Nakagomi, S., Barsoum, M. J., Bossy-Wetzel, E., Sütterlin, C., Malhotra, V. and Lipton, S. A. (2008). A Golgi fragmentation pathway in neurodegeneration. *Neurobiol. Dis.* **29**, 221-231. doi:10.1016/j.nbd.2007.08.015
- O'Flanagan, C. H. and O'Neill, C. (2014). PINK1 signalling in cancer biology. *Biochim. Biophys. Acta* **1846**, 590-598. doi:10.1016/j.bbcan.2014.10.006
- O'Flanagan, C. H., Morais, V. A., Wurst, W., De Strooper, B. and O'Neill, C. (2015). The Parkinson's gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes. *Oncogene* **34**, 1363-1374. doi:10.1038/onc.2014.81
- Ohta, E., Kawakami, F., Kubo, M. and Obata, F. (2011). LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. *FEBS Lett.* **585**, 2165-2170. doi:10.1016/j.febslet.2011.05.044
- Papakonstanti, E. A., Ridley, A. J. and Vanhaesebroeck, B. (2007). The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. *EMBO J.* **26**, 3050-3061. doi:10.1038/sj.emboj.7601763
- Pedrosa, A. R., Bodrug, N., Gomez-Escudero, J., Carter, E. P., Reynolds, L. E., Georgiou, P. N., Fernandez, I., Lees, D. M., Kostourou, V., Alexopoulou, A. N. et al. (2019). Tumor angiogenesis is differentially regulated by phosphorylation of endothelial cell focal adhesion kinase tyrosines-397 and -861. *Cancer Res.* **79**, 4371-4386. doi:10.1158/0008-5472.CAN.18-3934
- Peng, W., Lei, Q., Jiang, Z. and Hu, Z. (2014). Characterization of Golgi scaffold proteins and their roles in compartmentalizing cell signaling. *J. Mol. Histol.* **45**, 435-445. doi:10.1007/s10735-013-9560-1
- Pils, A. and Winkhofer, K. F. (2012). Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. *Acta Neuropathol.* **123**, 173-188. doi:10.1007/s00401-011-0902-3
- Pridgeon, J. W., Olzmann, J. A., Chin, L.-S. and Li, L. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. *PLoS Biol.* **5**, e172. doi:10.1371/journal.pbio.0050172
- Rabinovsky, R., Pochanard, P., McNear, C., Brachmann, S. M., Duke-Cohan, J. S., Garaway, L. A. and Sellers, W. R. (2009). p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. *Mol. Cell. Biol.* **29**, 5377-5388. doi:10.1128/MCB.01649-08
- Rendon, W. O., Martínez-Alonso, E., Tomás, M., Martínez-Martínez, N. and Martínez-Menárguez, J. A. (2013). Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease. *Histochem. Cell Biol.* **139**, 671-684. doi:10.1007/s00418-012-1059-4
- Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., Doring, M. J., Kholodilov, N. and Burke, R. E. (2006). Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. *Proc. Natl. Acad. Sci. USA* **103**, 18757-18762. doi:10.1073/pnas.0606401103
- Salamon, R. S. and Backer, J. M. (2013). Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases. *BioEssays* **35**, 602-611. doi:10.1002/bies.201200176
- Sánchez-Mora, R. M., Arboleda, H. and Arboleda, G. (2012). PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway. *J. Mol. Neurosci.* **47**, 582-594. doi:10.1007/s12031-011-9687-z
- Sandebing, A., Thomas, K. J., Beilina, A., van Der Brug, M., Cleland, M. M., Ahmad, R., Miller, D. W., Zambrano, I., Cowburn, R. F., Behbahani, H. et al. (2009). Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. *PLoS ONE* **4**, e5701. doi:10.1371/journal.pone.0005701
- Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and rapator-independent pathway that regulates the cytoskeleton. *Curr. Biol.* **14**, 1296-1302. doi:10.1016/j.cub.2004.06.054
- Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* **307**, 1098-1101. doi:10.1126/science.1106148
- Sato, M., Ueda, Y., Takagi, T. and Umezawa, Y. (2003). Production of PtdInsP3 at endomembranes is triggered by receptor endocytosis. *Nat. Cell Biol.* **5**, 1016-1022. doi:10.1038/ncb1054
- Seo, J.-H., Rah, J.-C., Choi, S. H., Shin, J. K., Min, K., Kim, H.-S., Park, C. H., Kim, S., Kim, E.-M., Lee, S.-H. et al. (2002). Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. *FASEB J.* **16**, 1826-1828. doi:10.1096/fj.02-0041fj
- Sha, D., Chin, L.-S. and Li, L. (2010). Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF- κ B signaling. *Hum. Mol. Genet.* **19**, 352-363. doi:10.1093/hmg/ddp501
- Shiba-Fukushima, K., Imai, Y., Yoshida, S., Ishihama, Y., Kanao, T., Sato, S. and Hattori, N. (2012). PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. *Sci. Rep.* **2**, 1002. doi:10.1038/srep01002
- Siddhanta, A., Radulescu, A., Stankewich, M. C., Morrow, J. S. and Shields, D. (2003). Fragmentation of the Golgi apparatus. A role for β III spectrin and synthesis of phosphatidylinositol 4,5-bisphosphate. *J. Biol. Chem.* **278**, 1957-1965. doi:10.1074/jbc.M209137200
- Soutar, M. P. M., Kempthorne, L., Miyakawa, S., Annuario, E., Melandri, D., Harley, J., O'Sullivan, G. A., Wray, S., Hancock, D. C., Cookson, M. R. et al. (2018). AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons. *Sci. Rep.* **8**, 8855. doi:10.1038/s41598-018-26949-6
- Steer, E. K., Dail, M. K. and Chu, C. T. (2015). Beyond mitophagy: cytosolic PINK1 as a messenger of mitochondrial health. *Antioxid Redox Signal.* **22**, 1047-1059. doi:10.1089/ars.2014.6206

- Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. and Hawkins, P. T.** (1997). Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* **277**, 567-570. doi:10.1126/science.277.5325.567
- Thorpe, L. M., Spangle, J. M., Ohlson, C. E., Cheng, H., Roberts, T. M., Cantley, L. C. and Zhao, J. J.** (2017). PI3K-p110 α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85 α . *Proc. Natl. Acad. Sci. USA* **114**, 7095-7100. doi:10.1073/pnas.1704706114
- Timmons, S., Coakley, M. F., Moloney, A. M. and O'Neill, C.** (2009). Akt signal transduction dysfunction in Parkinson's disease. *Neurosci. Lett.* **467**, 30-35. doi:10.1016/j.neulet.2009.09.055
- Tsolakos, N., Durrant, T. N., Chessa, T., Suire, S. M., Oxley, D., Kulkarni, S., Downward, J., Perisic, O., Williams, R. L., Stephens, L. and et al.** (2018). Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. *Proc. Natl. Acad. Sci. USA* **115**, 12176-12181. doi:10.1073/pnas.1803446115
- Unoki, M. and Nakamura, Y.** (2001). Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. *Oncogene* **20**, 4457-4465. doi:10.1038/sj.onc.1204608
- Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G. et al.** (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* **304**, 1158-1160. doi:10.1126/science.1096284
- Vanhauwaert, R., Kuenen, S., Masius, R., Bademosi, A., Manetsberger, J., Schoovaerts, N., Bounti, L., Gontcharenko, S., Swerts, J., Vilain, S. et al.** (2017). The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic terminals. *EMBO J.* **36**, 1392-1411. doi:10.15252/embj.201695773
- Vincow, E. S., Merrihew, G., Thomas, R. E., Shulman, N. J., Beyer, R. P., Maccoss, M. J. and Pallanck, L. J.** (2013). The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. *Proc. Natl. Acad. Sci. USA* **110**, 6400-6405. doi:10.1073/pnas.1221132110
- Wang, Y., Weiss, L. M. and Orlofsky, A.** (2010). Coordinate control of host centrosome position, organelle distribution, and migratory response by *Toxoplasma gondii* via host mTORC2. *J. Biol. Chem.* **285**, 15611-15618. doi:10.1074/jbc.M109.095778
- Watson, S. J. and Downward, J.** (1999). Akt/PKB localisation and 3' phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction. *Curr. Biol.* **9**, 433-436. doi:10.1016/S0960-9822(99)80192-4
- Wenk, M. R. and De Camilli, P.** (2004). Protein-lipid interactions and phosphoinositide metabolism in membrane traffic: insights from vesicle recycling in nerve terminals. *Proc. Natl. Acad. Sci. USA* **101**, 8262-8269. doi:10.1073/pnas.0401874101
- Wick, M. J., Ramos, F. J., Chen, H., Quon, M. J., Dong, L. Q. and Liu, F.** (2003). Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. *J. Biol. Chem.* **278**, 42913-42919. doi:10.1074/jbc.M304172200
- Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E. et al.** (2008). PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. *PLoS ONE* **3**, e2455. doi:10.1371/journal.pone.0002455
- Xiong, H., Wang, D., Chen, L., Choo, Y. S., Ma, H., Tang, C., Xia, K., Jiang, W., Ronai, Z., Zhuang, X. et al.** (2009). Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. *J. Clin. Invest.* **119**, 650-660. doi:10.1172/JCI37617
- Yang, J., Cron, P., Good, V. M., Thompson, V., Hemmings, B. A. and Barford, D.** (2002). Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. *Nat. Struct. Biol.* **9**, 940-944. doi:10.1038/nsb870
- Yang, W., Wang, X., Liu, J., Duan, C., Gao, G., Lu, L., Yu, S. and Yang, H.** (2018). PINK1 suppresses alpha-synuclein-induced neuronal injury: a novel mechanism in protein phosphatase 2A activation. *Oncotarget* **9**, 37-53. doi:10.18632/oncotarget.21554
- Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L. et al.** (2011). First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. *J. Clin. Oncol.* **29**, 4688-4695. doi:10.1200/JCO.2011.35.5263
- Youle, R. J. and Narendra, D. P.** (2011). Mechanisms of mitophagy. *Nat. Rev. Mol. Cell Biol.* **12**, 9-14. doi:10.1038/nrm3028
- Youle, R. J. and van der Bliek, A. M.** (2012). Mitochondrial fission, fusion, and stress. *Science* **337**, 1062-1065. doi:10.1126/science.1219855
- Zhang, Y., Gong, X.-G., Wang, Z.-Z., Sun, H.-M., Guo, Z.-Y., Hu, J.-H., Ma, L., Li, P. and Chen, N.-H.** (2016). Overexpression of DJ-1/PARK7, the Parkinson's disease-related protein, improves mitochondrial function via Akt phosphorylation on threonine 308 in dopaminergic neuron-like cells. *Eur. J. Neurosci.* **43**, 1379-1388. doi:10.1111/ejn.13216
- Zheng, J., Fan, R., Wu, H., Yao, H., Yan, Y., Liu, J., Ran, L., Sun, Z., Yi, L., Dang, L. et al.** (2019). Directed self-assembly of herbal small molecules into sustained release hydrogels for treating neural inflammation. *Nat. Commun.* **10**, 1604. doi:10.1038/s41467-019-09601-3
- Ziviani, E., Tao, R. N. and Whitworth, A. J.** (2010). Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. *Proc. Natl. Acad. Sci. USA* **107**, 5018-5023. doi:10.1073/pnas.0913485107